EWEsko Wiltshire

Esko Wiltshire

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Esko Wiltshire has a total of 304 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Experiences with Simplera sync™ all‐in‐one sensors and extended wear infusion sets in adolescents and young adults using the MiniMed ™ 780G : A qualitative study

    by Venus R. Michaels, Hamish R. Crocket, Alisa Boucsein, Yongwen Zhou, Ryan G. Paul, Esko Wiltshire, Craig Jefferies, Martin I. de Bock, Benjamin J. Wheeler

    Aims: To evaluate the real‐world user experience of young people (7–25 years) with type 1 diabetes and previously very elevated glycaemia (≥69 mmol/mol) transitioning from the MiniMed™ 780G advanced hybrid closed‐loop (AHCL) system with Guardian™ 4 continuous glucose monitoring systems (CGM) and 3‐day infusion sets to the upgraded system with Simplera Sync™ all‐in‐one CGM and 7‐day Extended™ wear infusion sets (EIS). Methods: Qualitative interviews were conducted with 11 participants from the CO‐PILOT trial extension phase who had used the upgraded system for at least 4 weeks. Thematic analysis was used to identify aspects of the technology transition that reduced, continued, or did not affect the burden of diabetes care and technology. Results: Participants reported several burden‐reducing aspects of the upgraded system, including easier, independent insertion of both sensors and infusion sets, improved device design (slimmer profile, one‐piece disposable design), reduced frequency of equipment changes, and decreased psychosocial burden. Aspects with ongoing burden included premature sensor failures, connection issues between pump and sensor, adhesion problems, and concerns about alarm functionality. Trust in the AHCL system remained high across both systems for most participants. Conclusion: The transition from Guardian™ 4 and 3‐day infusion sets to Simplera Sync™ and EIS was overall positive, with participants reporting enhanced user experience, greater convenience, and improved autonomy. However, challenges with premature sensor failure and alarm functionality were identified at times. These findings highlight the importance of continued technological advancement while maintaining multiple options to accommodate individual needs and preferences.


  • Open Access

    The KiwiDiab First National Paediatric Diabetes Benchmarking Audit: A Report on Children and Adolescents With Diabetes in Aotearoa New Zealand 2023

    by Jonathan Williman, Martin de Bock, Ben Wheeler, Vicki Cunningham, Fran Mouat, Yiing Yiing Goh, Maryam Mussa, Mark Shaw, Jeremy Armishaw, Rhian Teaz, et al.

    Aim: To compare demographics, therapeutics and outcomes in children and adolescents with diabetes in Aotearoa, New Zealand from the KiwiDiab network. Methods: All cases of type 1 diabetes (T1D) and type 2 diabetes (T2D) from the 13 regional centres that provide care were collated for the 2023 calendar year. Results: There were 1849 children and adolescents with diabetes: 1642 (88.8%) had T1D, mean age at diagnosis 9 years (interquartile range [IQR]: 6–12), mean age in clinic 12 years (IQR: 9–14); 47% were female and 69% identified as NZ European, 16% Māori and 8.3% Pacific. Overall, 23% of children and adolescents with T1D achieved an HbA1c level < 53 mmol/mol (7.0%). The mean (±standard deviation) HbA1c for any insulin pump use was 59 ± 11 mmol/mol (7.5% ± 1.0%) compared to 72 ± 19 (8.7% ± 1.8%) for those on multi‐daily injections (MDI) and 96 ± 25 (11.0% ± 2.3%) on twice‐daily (BD) insulin ( p < 0.001). For the 23% of those using automated insulin delivery, mean HbA1c was similar across ethnic groups. However, HbA1c was higher for those on MDI or BD of Pacific or Māori versus European or Asian ethnicity ( p < 0.001). There were 151/1849 (8.2%) children and adolescents with T2D: mean age at diagnosis 13 years (IQR: 12–14), age in clinic 14 years (IQR: 12–15); 61% were female, 38% Māori and 42% Pacific. Conclusions: This inaugural national benchmarking report demonstrates the differences in diabetes technology usage and HbA1c levels for children and adolescents in Aotearoa, New Zealand. This highlights the need for ongoing benchmarking activities on a regular basis.


  • Open Access

    Impact of automated insulin delivery on subjective and objective sleep in children and young adults with very high HbA1c : Sleep outcomes from the CO ‐ PILOT randomised controlled trial

    by Venus R. Michaels, Alisa Boucsein, Jillian J. Haszard, Barbara Galland, Kim A. Meredith‐Jones, Yongwen Zhou, Shirley D. Jones, Ryan G. Paul, Esko Wiltshire, Craig Jefferies, et al.

    Aims: To assess how automated insulin delivery (AID) impacts sleep in young people with type 1 diabetes and suboptimal glycaemia (HbA1c ≥ 69 mmol/mol). Methods: We conducted a randomised controlled trial comparing AID to usual care in 80 participants (aged 7–25 years) over 13 weeks. Sleep was a secondary outcome assessed at baseline and 13 weeks using questionnaires (subjective) and accelerometry (objective). Results: All participants completed the trial; 64 provided subjective and 40 provided objective sleep data. Participants reported poor subjective sleep quality alongside high levels of sleep disturbance and sleep‐related impairment at both timepoints. At 13 weeks, sleep‐related impairment improved more in the intervention group than in controls (MD = −4.7; 95% CI = −8.7, −0.8; p = 0.02), with no between‐group differences in other subjective measures. Accelerometry data showed the intervention group spent 21 more minutes awake after sleep onset (WASO) (MD = 21; 95% CI = 1, 41; p = 0.04) and experienced a 4 percentage point decline in sleep efficiency (MD = −4.2; 95% CI = −8.0, −0.3; p = 0.03), compared to controls after 13 weeks. These results paralleled substantial improvements in HbA1c for intervention participants compared to controls (MD = −34 mmol/mol; 95% CI = −43, −25; p ‐value <0.001). Conclusion: Although AID improved some subjective sleep aspects, sleep efficiency reduced and WASO increased. The relationship between glycaemia and sleep remains unclear, suggesting that effective sleep improvement in young people with T1D may require multifactorial approaches extending beyond improving glycaemia.


  • Open Access

    Impact of Simplera Sync™ sensors and Extended™ Wear Infusion Sets on glycaemia and system performance of the MiniMed ™ 780G system in children and young adults with previously high HbA1c

    by Venus R. Michaels, Alisa Boucsein, Yongwen Zhou, Shirley D. Jones, Ryan G. Paul, Esko Wiltshire, Craig Jefferies, Martin I. de Bock, Benjamin J. Wheeler

    Aims: The MiniMed™ 780G improves glycaemia and reduces burden in type 1 diabetes. We investigated how new all‐in‐one “Simplera Sync™” sensors and 7‐day Extended™ Wear Infusion Sets (EIS) affect glycaemia and system performance in young people with previously elevated HbA1c levels (≥69 mmol/mol [≥8%]) after transitioning from 780G with Guardian 4™ sensors and 3‐day infusion sets. Methods: We conducted an extension phase analysis in 75 participants (aged 7–25 years) initially enrolled in the CO‐PILOT randomised controlled trial. For this analysis, baseline was defined as the period following the use of 780G with Guardian 4™ sensors and 3‐day infusion sets. Participants then transitioned to 780G with Simplera Sync™ and EIS. We compared glycaemic and system performance outcomes from baseline to those after the transition to 780G with Simplera Sync™ and EIS. Results: Baseline HbA1c was 66.1 mmol/mol ± 14.2 mmol/mol and remained stable at 66.7 mmol/mol ± 11.2 mmol/mol after the transition ( p = 0.38). Time in range (3.9–10.0 mmol/L [70–180 mg/dL]) at baseline was 58.5% ± 14.9% and 60.4% ± 15.7% after transition ( p = 0.09). Time in tight range (3.9–7.8 mmol/L [70–140 mg/dL]) increased from 38.1% ± 13.1% at baseline to 40.5% ± 13.6% after the transition ( p = 0.04). While using 780G with Simplera Sync™ and EIS, automation time increased from baseline 79.2% ± 25.9% to 85.8% ± 21.8% ( p = 0.007), and sensor wear time from 80.7% ± 22.4% at baseline to 88.4% ± 17.2% ( p < 0001). Conclusions: Simplera Sync™ and EIS improved time in automation and sensor wear time when using 780G AHCL in this high‐risk young population. This was associated with incremental improvement in time in tight range despite the challenges of this population.


  • Open Access

    Identification of DICER1 Syndrome on the Basis of Familial, Early‐Onset Differentiated Thyroid Cancer

    by Jessica Y. Wong, Alex Henderson, Simon Harper, Richard W. Carroll, Peter B. Bethwaite, Esko Wiltshire

    DICER1 syndrome encompasses a wide range of phenotypes, and not all individuals with DICER1 syndrome develop aggressive soft tissue tumors. DICER1 syndrome and other genetic conditions predisposing to the development of thyroid tumors should be considered when a young patient presents with thyroid nodules and a positive family history.


  • Open Access

    Predictors of glycaemic improvement in children and young adults with type 1 diabetes and very elevated HbA1c using the MiniMed 780G system

    by Yongwen Zhou, Alisa Boucsein, Venus R. Michaels, Madeleine K. Gray, Craig Jefferies, Esko Wiltshire, Ryan G. Paul, Amber Parry‐Strong, Maheen Pasha, Goran Petrovski, et al.

    Aims: This study aimed to identify key factors with the greatest influence on glycaemic outcomes in young individuals with type 1 diabetes (T1D) and very elevated glycaemia after 3 months of automated insulin delivery (AID). Materials and Methods: Data were combined and analysed from two separate and previously published studies with similar inclusion criteria assessing AID (MiniMed 780G) efficacy among young individuals naïve to AID (aged 7–25 years) with glycated haemoglobin A1c (HbA1c) ≥69 mmol/mol (≥8.5%). Univariate and multivariate linear models were performed to explore factors leading to the greatest improvements in HbA1c and time in range 3.9–10.0 mmol/L (70–180 mg/dL; TIR). Results: A total of 99 young individuals (aged 17.3 ± 4.2 years; baseline HbA1c 92 ± 21 mmol/mol [10.6% ± 1.9%]) were included. After 3 months of AID use, HbA1c improved to 65 ± 16 mmol/mol (8.1% ± 1.5%) (−27 ± 23 mmol/mol; −2.5% ± 2.1% change), and TIR improved from 24.2% ± 13.5% to 58.4% ± 15.4% ( p both 100 mmol/mol [>11.0%]) and high time in automation mode (>80%), which led to decreased HbA1c by 27.0 mmol/mol (2.4%) and 14.2 mmol/mol (1.3%) and increased TIR by 6.1% and 11.1% ( p all 3 times/day and glucose target of 5.5 mmol/L (100 mg/dL) also led to significant increases in TIR. No other factors, including age, prior use of multiple daily injection, ethnicity, gender and optimal active insulin time 2 h, contributed to statistically significant HbA1c or TIR improvement. Conclusions: In young individuals naive to AID, those with the highest baseline HbA1c and high percentage time in automation experience the greatest benefits after initiation of AID. Sociodemographic background and carbohydrate counting adherence/knowledge should not prevent or delay access to AID technology (ACTRN12621000556842 and ACTRN12622001454763).


  • Open Access

    Protocol for a prospective, multicenter, parallel-group, open-label randomized controlled trial comparing standard care with Closed lOoP In chiLdren and yOuth with Type 1 diabetes and high-risk glycemic control: the CO-PILOT trial

    by Alisa Boucsein, Yongwen Zhou, Jillian J. Haszard, Craig A. Jefferies, Esko J. Wiltshire, Sara E. Styles, Hamish R. Crocket, Barbara C. Galland, Maheen Pasha, Goran Petrovski, et al.

    Purpose: Advanced hybrid closed loop (AHCL) systems have the potential to improve glycemia and reduce burden for people with type 1 diabetes (T1D). Children and youth, who are at particular risk for out-of-target glycemia, may have the most to gain from AHCL. However, no randomized controlled trial (RCT) specifically targeting this age group with very high HbA1c has previously been attempted. Therefore, the CO-PILOT trial (Closed lOoP In chiLdren and yOuth with Type 1 diabetes and high-risk glycemic control) aims to evaluate the efficacy and safety of AHCL in this group. Methods: A prospective, multicenter, parallel-group, open-label RCT, comparing MiniMed™ 780G AHCL to standard care (multiple daily injections or continuous subcutaneous insulin infusion). Eighty participants aged 7–25 years with T1D, a current HbA1c ≥ 8.5% (69 mmol/mol), and naïve to automated insulin delivery will be randomly allocated to AHCL or control (standard care) for 13 weeks. The primary outcome is change in HbA1c between baseline and 13 weeks. Secondary outcomes include standard continuous glucose monitor glycemic metrics, psychosocial factors, sleep, platform performance, safety, and user experience. This RCT will be followed by a continuation phase where the control arm crosses over to AHCL and all participants use AHCL for a further 39 weeks to assess longer term outcomes. Conclusion: This study will evaluate the efficacy and safety of AHCL in this population and has the potential to demonstrate that AHCL is the gold standard for children and youth with T1D experiencing out-of-target glucose control and considerable diabetes burden. Trial registration: This trial was prospectively registered with the Australian New Zealand Clinical Trials Registry on 14 November 2022 (ACTRN12622001454763) and the World Health Organization International Clinical Trials Registry Platform (Universal Trial Number U1111-1284-8452).


  • Open Access

    Subsequent Device Usage and Caregiver Attitudes to Do-It-Yourself Real-Time Continuous Glucose Monitoring (DIY-rtCGM) among Children with Type 1 Diabetes 3 Months after Participation in a Randomized Controlled Trial

    by Yongwen Zhou, Mona M. Elbalshy, Sara E. Styles, Hamish Crocket, Craig Jefferies, Esko Wiltshire, Martin I. de Bock, Benjamin J. Wheeler

    Aim. To assess childrens subsequent device usage and caregiver attitudes to do-it-yourself real-time continuous glucose monitoring (DIY-rtCGM) at least 3 months after completing a randomized controlled trial (RCT). Methods. A brief online questionnaire or telephone call was used to collect the subsequent device usage and caregivers attitudes from a total of 55 families at least 3 months after their completion of an RCT investigating DIY-rtCGM adapted from their preexisting intermittently scanned glucose sensors plus education on using DIY-rtCGM system. To be eligible for the RCT, children had to be aged 213 years, have type 1 diabetes 6 months, and be rtCGM nave. Data collected investigated current CGM use post-RCT and attitudes/user experiences to DIY-rtCGM in the months since RCT study support ended. Results. Overall, responses from 81.8 (45/55) of caregivers were received. Mean age of children was 9.02.7 years, and 31 (68.9) children used insulin pumps. After 3 months, 44.4 (20/45) of responding caregivers reported ongoing DIY-rtCGM use, and of these, only 13 used DIY-rtCGM as the primary glucose monitoring method 100 of time. Of the 25 (55.6) families who ceased DIY-rtCGM, 40 (10/25) had transitioned to commercial rtCGM. More than half of families (60, 12/20) who continued DIY-rtCGM use had a very or extremely positive attitude toward the technology and 75 (15/20) of these families planned to continue DIY-rtCGM use. However, signal loss and sensor inaccuracy remained the major reasons among all responders both for decreased DIY-rtCGM wear time and eventual cessation. Burden of use primarily related to technical errors that could not be solved, and alarms, both of which were reported to contribute to discontinuation. Conclusions. This study highlights that, among families voluntarily using DIY-rtCGM at least 3 months following support from a trial, more than half have ceased using DIY-rtCGM, with 40 of those discontinuing switching to commercial rtCGM. While overall perceptions of DIY-rtCGM remain largely positive, burdens of use are high and contribute to discontinuation.

  • Open Access

    Impact of 6 months’ Use of Intermittently Scanned Continuous Glucose Monitoring on Habitual Sleep Patterns and Sleep Quality in Adolescents and Young Adults with Type 1 Diabetes and High-Risk HbA1c

    by Shelley Rose, Barbara C. Galland, Sara E. Styles, Esko J. Wiltshire, James Stanley, Martin I. de Bock, Paul A. Tomlinson, Jenny A. Rayns, Benjamin J. Wheeler

    Background. The bidirectional relationship between sleep and blood glucose levels may particularly affect adolescents and young adults (AYA), who are more likely to experience less healthy glycemic outcomes and more disrupted sleep patterns. To date, few data exist describing the impact of intermittently scanned continuous glucose monitoring (isCGM) on habitual sleep patterns and sleep quality in AYA with type 1 diabetes (T1D). Objective. To evaluate the impact of 6-month use of isCGM on habitual sleep and wake timing, sleep duration, frequency, and duration of night-time awakenings, sleep efficiency, and perceived sleep quality in young people with T1D and HbA1c75mmol/mol. Participants. The study recruited 64 participants aged 1320years (mean 16.6±2.1), 48 female, diabetes duration 7.5±3.8years, 41 Māori or Pasifika, and a mean HbA1c 96.0±18.0mmol/mol [10.9±3.8]; 33 were allocated to an isCGM plus self-monitoring blood glucose [SMBG] intervention, and 31 were allocated to the SMBG control group. Methods. Participants completed 7-day actigraphy measures and the Pittsburgh Sleep Quality Index questionnaire at the baseline and at 6months. Regression analyses were used to model between-group comparisons, adjusted for baseline sleep measures. Results. At 6months, subjective measures for overall sleep quality, latency, duration, efficiency, night-time disturbances, use of sleep medications, and daytime dysfunction were similar between the groups. Regression analyses of actigraphy found no significant differences in objectively measured sleep timing and duration across the week after adjusting for age, the period of the school year, and baseline sleep values. Conclusions. The use of first-generation isCGM in addition to finger-prick testing did not impact objective or subjective sleep measures in AYA with T1D, elevated HbA1c, and highly variable sleep patterns. Research using alternative interventions for improving glycemic outcomes and habitual sleep-wake timing, duration, and perceived sleep quality is warranted in this population group.


  • Open Access

    Perceptions and Experiences of Using Intermittently Scanned Continuous Glucose Monitoring among Youth Ages 13–20 Years with Type 1 Diabetes and Above Recommended HbA1c: A Qualitative Study

    by Sara E. Styles, Hamish R. Crocket, Esko J. Wiltshire, Martin I. de Bock, Benjamin J. Wheeler

    The experiences of youth with high-risk glycaemic control using intermittently scanned continuous glucose monitoring (isCGM) systems are not well known. In the context of a randomised controlled trial investigating a 6-month isCGM intervention, this sub-study aimed to explore the experiences of youth using isCGM for 6 months. Semi-structured interviews were conducted with 14 youth aged 14–20 years who had Type 1 diabetes for ≥12 months and a glycated haemoglobin (HbA1c) of ≥75 mmol/mol (≥9%) pre-isCGM intervention. Interviews were recorded, transcribed and coded using Nvivo. A thematic analytic approach was used to identify key themes overall and by comparing participants who at 6 months had: (1) experienced a ≥10 mmol/L (0.9%) reduction in HbA1c and (2) sustained scanning frequency ≥3/day to those who did not. All participants expressed a strong preference for isCGM over self-monitoring blood glucose. Overall, isCGM contributed to perceived reduced diabetes burden without a requirement for more support in diabetes management. Increased engagement with self-management, including successful changes in dosage of basal or bolus insulin and increased frequency of administration of insulin, were behaviours reported by those experiencing the greatest improvement in HbA1c (>10 mmol/L [>0.9%], n = 6). They noted feeling more energetic, thus, making it easier to maintain self-management behaviours. Most youths reported best practices, such as following prompts to rescan in 10 min and timely sensor replacement; however, most did not check capillary blood glucose levels in recommended situations. Over 6 months, youth with high-risk diabetes experienced isCGM as a useful short-term tool for overcoming diabetes burden and facilitating self-management.